-
#IAmJaneDoe: online support campaign in US university rape case
-
Trainer Scott gets perfect Arc boost with top notch double
-
Brazil shine on Selecao's first visit to India
-
Ex-PM says Putin cannot admit 'mistake' over Ukraine
-
Zverev sets up Djokovic quarter-final at China Open, Rybakina out
-
Houthis say Saudi Arabia launches dozens of strikes on Yemen capital
-
Happier at home, Bordeaux hammer Lyon in Top 14
-
Qatar and Abu Dhabi F1 Grand Prix to go ahead - F1 boss
-
Lula, Bolsonaro in final push for votes ahead of knife-edge election
-
South Korea lift gloom with smash-and-grab Games football gold
-
Boisterous fashion week barnstorms 'sleepy' Nigerian capital
-
Ireland news conference before Israel game cut short amid tensions
-
UAE investigators say flydubai co-pilot was planning 'terrorist act'
-
Protests over housing flare in Spain after relief measures rejected
-
Rahul smacks century in India v Windies ODI
-
Zverev thrashes Shang to set up Djokovic quarter-final at China Open
-
Daryz seeks to join exclusive club of dual Arc winners
-
Turkey football ref chief jailed pending trial for graft
-
Russia warns diplomats to leave Kyiv over new strikes threat
-
North Korea says test of intermediate-range strategic missile included use of AI
-
Olympic champ Zheng rebukes rowdy home crowd at China Open
-
Rampant Sayers leads Hong Kong to third men's rugby gold in a row
-
World No.1 Sinner pulls out of Shanghai Masters to delay return
-
Ethiopia's Tigray rebels abandon regional capital as govt advances
-
Red Bull's Verstappen grabs pole position for Bahrain GP
-
Bulgaria's Tsar Samuel returns 'home' after 1,000 years
-
India beat Pakistan in blockbuster as golfer Kim wins 'crazy' gold
-
'Glad it's over': Kim powers to Games gold and military exemption
-
India beat arch-rivals Pakistan to win Asian Games cricket gold
-
After 11 World Cups, football finally comes home for one Indian fan
-
Ethiopia's Tigray rebels abandon regional capital as govt advances: journalist
-
Marc Marquez wins sprint at Japan MotoGP, Martin grabs pole
-
Tom Kim powers to Games gold and exemption from military service
-
Alcaraz fends off Arnaldi to reach Japan Open quarters
-
Split loyalties for Indian football fans at Brazil friendly
-
Antonelli tops times in final practice at Bahrain GP
-
India-Pakistan blockbuster brings cricket fever to Japan baseball field
-
Gauff digs deep to beat Osorio in China Open second round
-
Wong waiting on Rafa after winning Asian Games tennis gold
-
Fresh protests to hit Spain after housing measures defeated
-
With Russia next door and rising costs, Latvia goes to the polls
-
'He's here with me': Japan cycle queen dedicates gold to late brother
-
Penalty hero rues empty seats as Games hosts Japan win football gold
-
Japan Olympic chief says 'lot more' athletes at Games than expected
-
North Korea fires ballistic missile after Seoul's apology demand
-
Asian carmakers besting US rivals at home, China poised to strike
-
US regulator finds Boeing 737 MAX software bug 'not a safety concern'
-
Widgets & Web Offers All-Inclusive Investor Relations Websites for Public Companies, IPOs and SPACs
-
Ohtani 'managing' injuries as Dodgers launch MLB post-season
-
Adams named new US captain to 2030 World Cup
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Schubert--BTB